Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Novartis
Novartis
Novartis
Hoffmann-La Roche
AstraZeneca
Novartis
Hoffmann-La Roche
Pfizer
Eli Lilly and Company
Forward Pharmaceuticals Co., Ltd.
Stemline Therapeutics, Inc.
Avenzo Therapeutics, Inc.
Pfizer
Novartis
Array BioPharma